UK 600 mile rainstorm: When is it set to hit and which 8 counties will avoid it?

on
0

New Research Confirms Weight-Loss Drug Link With Sudden Vision Loss

on
Weight-Loss Drugs May Raise Risk of Sudden Vision Loss, New Research Shows

Weight-Loss Drugs May Raise Risk of Sudden Vision Loss, New Research Shows

Recent studies have raised concerns over a possible link between commonly prescribed weight-loss and diabetes medications—specifically GLP-1 agonists like Ozempic, Wegovy, and Mounjaro—and rare but serious eye conditions that can lead to sudden vision loss.

Key Findings at a Glance

  • These GLP-1 agonists mimic a hormone that controls hunger and blood sugar, but may slightly increase the risk of non-arteritic anterior ischemic optic neuropathy (NAION), also known as an “eye-stroke,” which causes sudden, painless vision loss. Recovery is often limited.:contentReference[oaicite:0]{index=0}
  • In one study of over 159,000 people with type 2 diabetes, about 0.04% of GLP-1 users versus 0.02% of non-users developed NAION. Another study found no clear NAION risk but did note slightly higher rates of worsening diabetic retinopathy.:contentReference[oaicite:1]{index=1}
  • A previous study from Harvard Medical School reported that diabetics on semaglutide were over 4× more likely, and obese patients nearly 8× more likely, to develop NAION. However, the absolute risk remains very low.:contentReference[oaicite:2]{index=2}
  • Additionally, evidence links GLP-1 drugs to mildly higher rates of macular degeneration in older diabetic patients, and health agencies are monitoring these potential side effects.:contentReference[oaicite:3]{index=3}
  • However, a long-term observational study suggests that most patients on semaglutide do not experience worsening diabetic eye disease—and some with severe conditions even showed improvements.:contentReference[oaicite:4]{index=4}

What Should Patients Do?

The risk of NAION remains rare. Still, it's crucial for at-risk individuals—such as those with high blood pressure, sleep apnea, or preexisting eye conditions—to discuss potential risks with their doctors. Regular eye exams, especially when starting GLP-1 therapy, can help catch early signs. And if sudden vision loss occurs, patients should stop the medication and seek immediate medical care.:contentReference[oaicite:5]{index=5}

Related News

Labels: GLP-1 Agonists

Comments

Post a Comment